K
Kristin G.-I. Mohn
Researcher at University of Bergen
Publications - 31
Citations - 2198
Kristin G.-I. Mohn is an academic researcher from University of Bergen. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 12, co-authored 23 publications receiving 1594 citations. Previous affiliations of Kristin G.-I. Mohn include Haukeland University Hospital & Norwegian Institute of Public Health.
Papers
More filters
Journal ArticleDOI
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
John Mair-Jenkins,Maria Saavedra-Campos,J Kenneth Baillie,Paul Cleary,Fu-Meng Khaw,Wei Shen Lim,Sophia Makki,Kevin Rooney,Jonathan S. Nguyen-Van-Tam,Charles R. Beck,Ana Mateus,Simone Reuter,Jinho Shin,Xiaolin Xu,Dmitriy Pereyaslov,Irina Papieva,Anders Tegnell,Hélène Englund,Åsa Elfving,Rebecca Jane Cox,Kristin G.-I. Mohn,Yingjie Feng Jenkins +21 more
TL;DR: Convalescent plasma may reduce mortality and appears safe, and should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection.
Journal ArticleDOI
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Stella G. Muthuri,Sudhir Venkatesan,Puja R. Myles,Jo Leonardi-Bee,Tarig Saleh Al Khuwaitir,Adbullah Al Mamun,Ashish P Anovadiya,Eduardo Azziz-Baumgartner,Clarisa Báez,Matteo Bassetti,Bojana Beović,Barbara Bertisch,Isabelle Bonmarin,Robert Booy,Víctor Hugo Borja-Aburto,Heinz Burgmann,Bin Cao,Jordi Carratalà,Justin T Denholm,Samuel R. Dominguez,Péricles Almeida Delfino Duarte,Gal Dubnov-Raz,Marcela Echavarria,Sergio Fanella,Zhancheng Gao,Patrick Gérardin,Maddalena Giannella,Sophie Gubbels,Jethro Herberg,A. Iglesias,Peter Höger,Xiaoyun Hu,Quazi Tarikul Islam,Mirela Foresti Jiménez,Amr Kandeel,Gerben Keijzers,Hossein Khalili,Marian Knight,Koichiro Kudo,Gabriela Kusznierz,Ilija Kuzman,Arthur M C Kwan,Idriss Lahlou Amine,Eduard Langenegger,Kamran Bagheri Lankarani,Yee-Sin Leo,Rita Linko,Pei Liu,Faris Madanat,Elga Mayo-Montero,Allison McGeer,Ziad A. Memish,Gökhan Metan,Auksė Mickiene,Dragan Mikić,Kristin G.-I. Mohn,Kristin G.-I. Mohn,Ahmadreza Moradi,Ahmadreza Moradi,Pagbajabyn Nymadawa,Maria E. Oliva,Mehpare Ozkan,Dhruv Parekh,Mical Paul,Fernando P. Polack,Barbara Rath,Alejandro Rodríguez,Elena B. Sarrouf,Anna C. Seale,Anna C. Seale,Bunyamin Sertogullarindan,Marilda M. Siqueira,Joanna Skręt-Magierło,Frank P. Stephan,Ewa Talarek,Julian W. Tang,Julian W. Tang,Kelvin K. W. To,Antoni Torres,Selda Hançerli Törün,Dat Tran,Timothy M. Uyeki,Annelies van Zwol,Wendy Vaudry,Tjasa Vidmar,Renata T. C. Yokota,Paul Zarogoulidis,Jonathan S. Nguyen-Van-Tam +87 more
TL;DR: There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset, and early treatment versus no treatment was also associated with a reduction in mortality risk.
Journal ArticleDOI
Long COVID in a prospective cohort of home-isolated patients.
Bjørn Blomberg,Bjørn Blomberg,Kristin G.-I. Mohn,Kristin G.-I. Mohn,Karl A. Brokstad,Karl A. Brokstad,Fan Zhou,Dagrunn Waag Linchausen,Bernt-Are Hansen,Sarah Lartey,Therese Bredholt Onyango,Kanika Kuwelker,Marianne Sævik,Hauke Bartsch,Hauke Bartsch,Camilla Tøndel,Bård Reiakvam Kittang,Bård Reiakvam Kittang,Rebecca Jane Cox,Rebecca Jane Cox,Nina Langeland,Nina Langeland +21 more
TL;DR: In this paper, the authors conducted a long-term follow-up in a prospective cohort study of 312 patients-247 home-isolated and 65 hospitalized-comprising 82% of total cases in Bergen during the first pandemic wave in Norway.
Journal ArticleDOI
Immune responses after live attenuated influenza vaccination.
TL;DR: The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs, but despite 14 years on the global market, there exists no correlate of protection.
Journal ArticleDOI
Longevity of B-Cell and T-Cell Responses After Live Attenuated Influenza Vaccination in Children
Kristin G.-I. Mohn,Geir Bredholt,Karl A. Brokstad,Rishi D. Pathirana,Hans Jørgen Aarstad,Camilla Tøndel,Rebecca Jane Cox +6 more
TL;DR: LAIV elicited B-cell and T-cell responses that persisted for at least 1 year in children, which is a novel finding that will aid future vaccine policy.